203 related articles for article (PubMed ID: 9364979)
1. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
Kockx M; de Maat MP; Knipscheer HC; Kastelein JJ; Kluft C; Princen HM; Kooistra T
Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
[TBL] [Abstract][Full Text] [Related]
2. [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
Okopień B; Cwalina Ł; Haberka M; Kowalski J; Zieliński M; Szwed Z; Kalina Z; Herman ZS
Pol Merkur Lekarski; 2002 Dec; 13(78):465-9. PubMed ID: 12666442
[TBL] [Abstract][Full Text] [Related]
3. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
de Maat MP; Knipscheer HC; Kastelein JJ; Kluft C
Thromb Haemost; 1997 Jan; 77(1):75-9. PubMed ID: 9031453
[TBL] [Abstract][Full Text] [Related]
4. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
Vigna GB; Donega P; Passaro A; Zanca R; Cattin L; Fonda M; Pauciullo P; Marotta G; Fellin R; Gasparrini S; Piliego T
Nutr Metab Cardiovasc Dis; 1999 Oct; 9(5):234-43. PubMed ID: 10656170
[TBL] [Abstract][Full Text] [Related]
5. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Kockx M; Princen HM; Kooistra T
Thromb Haemost; 1998 Dec; 80(6):942-8. PubMed ID: 9869165
[TBL] [Abstract][Full Text] [Related]
6. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
8. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
Okopien B; Cwalina L; Lebek M; Kowalski J; Zielinski M; Wisniewska-Wanat M; Kalina Z; Herman ZS
Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
[TBL] [Abstract][Full Text] [Related]
9. Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes.
Zirlik A; Ernst S; Leugers A; Willecke F; Sobel BE; Bode C; Nordt TK
Thromb Haemost; 2009 Jun; 101(6):1060-9. PubMed ID: 19492148
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
Hamsten A; Syvänne M; Silveira A; Luong LA; Nieminen MS; Humphries S; Frick MH; Taskinen MR
Thromb Haemost; 2000 Mar; 83(3):397-403. PubMed ID: 10744143
[TBL] [Abstract][Full Text] [Related]
11. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
[TBL] [Abstract][Full Text] [Related]
12. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
Espinosa RA; Rodríguez-Roa E; Nagy E; Mijares ME; Rodríguez-Larralde A; Gil A; Lundberg U; Carvajal Z; Castillo L; Arocha-Piñango CL
Invest Clin; 2006 Mar; 47(1):35-48. PubMed ID: 16562643
[TBL] [Abstract][Full Text] [Related]
13. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
[TBL] [Abstract][Full Text] [Related]
14. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
[TBL] [Abstract][Full Text] [Related]
15. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
O'Neal DN; O'Brien RC; Timmins KL; Grieve GD; Lau KP; Nicholson GC; Kotowicz MA; Best JD
Diabet Med; 1998 Oct; 15(10):870-7. PubMed ID: 9796889
[TBL] [Abstract][Full Text] [Related]
16. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Branchi A; Rovellini A; Sommariva D; Gugliandolo AG; Fasoli A
Thromb Haemost; 1993 Aug; 70(2):241-3. PubMed ID: 8236126
[TBL] [Abstract][Full Text] [Related]
17. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
18. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men.
Johansson JO; Egberg N; Asplund-Carlson A; Carlson LA
J Cardiovasc Risk; 1997 Jun; 4(3):165-71. PubMed ID: 9475670
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
20. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
Balogh Z; Seres I; Harangi M; Kovács P; Kakuk G; Paragh G
Diabetes Metab; 2001 Nov; 27(5 Pt 1):604-10. PubMed ID: 11694861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
